Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukotriene modifiers in asthma management.

Valérie Capra1, G Enrico Rovati

  • 1University of Milan, Department of Pharmacological Sciences, Via Balzaretti, 9 20133 Milan, Italy.

Idrugs : the Investigational Drugs Journal
|July 10, 2004
PubMed
Summary

Asthma therapy should target chronic inflammation and airway remodeling, not just acute symptoms. Leukotriene modifiers offer a new treatment approach by inhibiting key inflammatory mediators involved in asthma progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

Exploiting the 2-(1,3,4,9-tetrahydropyrano[3,4-<i>b</i>]indol-1-yl)acetic Acid Scaffold to Generate COXTRANs: A New Class of Dual Cyclooxygenase Inhibitors-Thromboxane Receptor Antagonists.

Journal of medicinal chemistry·2025
Same author

G protein-coupled receptor (GPCR) pharmacogenomics.

Critical reviews in clinical laboratory sciences·2024
Same author

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.

British journal of pharmacology·2023
Same author

Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients.

Frontiers in pharmacology·2022
Same author

Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19.

Allergy·2022

Area of Science:

  • Pulmonology
  • Allergy and Immunology
  • Pharmacology

Background:

  • Asthma prevalence is rising, particularly in pediatric populations.
  • Asthmatic airways exhibit chronic inflammation and irreversible structural changes (remodeling) beyond acute symptoms.
  • Current asthma management often focuses on symptom relief, neglecting progressive airway remodeling.

Purpose of the Study:

  • To highlight the need for asthma therapies that prevent chronic inflammation and airway remodeling.
  • To emphasize the role of leukotrienes in both acute and chronic asthma.
  • To introduce leukotriene modifiers as a therapeutic option.

Main Methods:

  • Review of existing literature on asthma pathophysiology and treatment.
  • Analysis of the role of leukotrienes in early and late-phase asthma responses.
  • Discussion of the mechanism of action for leukotriene modifiers.

Main Results:

  • Leukotrienes are implicated in early bronchoconstriction and late-phase inflammation in asthma.
  • Chronic inflammation in asthma leads to progressive and irreversible airway remodeling.
  • Leukotriene modifiers effectively inhibit leukotriene synthesis or action.

Conclusions:

  • Therapeutic strategies for asthma must address chronic inflammation to prevent airway remodeling.
  • Leukotriene modifiers represent a significant advancement in asthma management by targeting a key inflammatory pathway.
  • Prescription leukotriene modifiers offer a targeted approach to managing the underlying inflammatory processes in asthma.

Related Experiment Videos